Christopher Nevala-Plagemann (Chris Nevala-Plagemann)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 6

Top Topics

Combination Therapy

Metastatic Breast Cancer

Squamous Cell Carcinoma

Top Venues

Nature reviews. Clinical oncology

Therapeutic advances in medical oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Christopher Nevala-Plagemann, Ignacio Garrido-Laguna
NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype? Nature reviews. Clinical oncology (2024)
Christopher Nevala-Plagemann, Ignacio Garrido-Laguna
NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype? Nature reviews. Clinical oncology 21 (8) (2024)
Vaia Florou, Andrew Elliott, Matthew H Bailey, David Stone, Kajsa E Affolter, Heloisa P Soares, Christopher Nevala-Plagemann, Courtney L Scaife, Phillip Walker, Wolfgang Michael Korn, Emil Lou, Rachna T Shroff, Peter J Hosein, Ignacio Garrido-Laguna
Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC)Unveils New Actionable Genomic Aberrations in PACC. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Siddharth Iyengar, Christopher Nevala-Plagemann, Ignacio Garrido-Laguna
Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma. Therapeutic advances in medical oncology 13 (2021)
Christopher Nevala-Plagemann, Manuel Hidalgo, Ignacio Garrido-Laguna
From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nature reviews. Clinical oncology 17 (2) (2019)
Christopher Nevala-Plagemann, Justin Moser, Glynn Weldon Gilcrease, Ignacio Garrido-Laguna
Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab. ESMO open 4 (4) (2019)